questionsmedicales.fr
Tumeurs
Tumeurs par siège
Tumeurs du thorax
Tumeurs du thorax : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Tumeurs thoraciques
Biopsie
Imagerie médicale
Tomodensitométrie
IRM
Bronchoscopie
Marqueurs tumoraux
Tumeurs thoraciques
Suivi médical
Histologie
Tumeurs thoraciques
Diagnostic
Tests génétiques
Tumeurs thoraciques
Traitement ciblé
Symptômes
5
Symptômes
Tumeurs thoraciques
Essoufflement
Perte de poids
Tumeurs thoraciques
Symptômes
Hémoptysie
Tumeurs thoraciques
Symptômes
Fatigue
Tumeurs thoraciques
Symptômes
Types de tumeurs
Tumeurs thoraciques
Symptômes
Prévention
5
Prévention
Tabagisme
Agents cancérigènes
Dépistage
Tumeurs thoraciques
Prévention
Alimentation
Prévention
Tumeurs thoraciques
Exercice physique
Prévention
Tumeurs thoraciques
Vaccination
Prévention
Cancers
Traitements
5
Chirurgie
Chimiothérapie
Radiothérapie
Chirurgie
Tumeurs thoraciques
Stade de la maladie
Chimiothérapie
Tumeurs thoraciques
Traitement néoadjuvant
Radiothérapie
Tumeurs thoraciques
Traitement complémentaire
Thérapies ciblées
Tumeurs thoraciques
Traitement
Complications
5
Complications
Métastase
Insuffisance respiratoire
Douleur thoracique
Tumeurs thoraciques
Complications
Difficultés respiratoires
Tumeurs thoraciques
Complications
Thrombose
Tumeurs thoraciques
Complications
Complications post-chirurgicales
Tumeurs thoraciques
Chirurgie
Facteurs de risque
5
Facteurs de risque
Tabagisme
Amiante
Âge
Facteurs de risque
Tumeurs thoraciques
Antécédents médicaux
Facteurs de risque
Tumeurs thoraciques
Exposition professionnelle
Facteurs de risque
Tumeurs thoraciques
Mode de vie
Facteurs de risque
Tumeurs thoraciques
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Tumeurs du thorax : Questions médicales les plus fréquentes",
"headline": "Tumeurs du thorax : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Tumeurs du thorax : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-21",
"dateModified": "2025-03-18",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Tumeurs du thorax"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tumeurs par siège",
"url": "https://questionsmedicales.fr/mesh/D009371",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs par siège",
"code": {
"@type": "MedicalCode",
"code": "D009371",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.588"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Adénocarcinome pulmonaire",
"alternateName": "Adenocarcinoma of Lung",
"url": "https://questionsmedicales.fr/mesh/D000077192",
"about": {
"@type": "MedicalCondition",
"name": "Adénocarcinome pulmonaire",
"code": {
"@type": "MedicalCode",
"code": "D000077192",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.588.894.797.520.055"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Adénocarcinome bronchioloalvéolaire",
"alternateName": "Adenocarcinoma, Bronchiolo-Alveolar",
"url": "https://questionsmedicales.fr/mesh/D002282",
"about": {
"@type": "MedicalCondition",
"name": "Adénocarcinome bronchioloalvéolaire",
"code": {
"@type": "MedicalCode",
"code": "D002282",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.588.894.797.520.055.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Blastome pulmonaire",
"alternateName": "Pulmonary Blastoma",
"url": "https://questionsmedicales.fr/mesh/D018202",
"about": {
"@type": "MedicalCondition",
"name": "Blastome pulmonaire",
"code": {
"@type": "MedicalCode",
"code": "D018202",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.588.894.797.520.867"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Tumeurs fibreuses solitaires de la plèvre",
"alternateName": "Solitary Fibrous Tumor, Pleural",
"url": "https://questionsmedicales.fr/mesh/D054363",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs fibreuses solitaires de la plèvre",
"code": {
"@type": "MedicalCode",
"code": "D054363",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.588.894.797.640.800"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs du thorax",
"alternateName": "Thoracic Neoplasms",
"code": {
"@type": "MedicalCode",
"code": "D013899",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Yan Wang",
"url": "https://questionsmedicales.fr/author/Yan%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China."
}
},
{
"@type": "Person",
"name": "Naseema Gangat",
"url": "https://questionsmedicales.fr/author/Naseema%20Gangat",
"affiliation": {
"@type": "Organization",
"name": "Mayo Clinic, Rochester, MN, USA."
}
},
{
"@type": "Person",
"name": "Anja C Roden",
"url": "https://questionsmedicales.fr/author/Anja%20C%20Roden",
"affiliation": {
"@type": "Organization",
"name": "Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, MN."
}
},
{
"@type": "Person",
"name": "Marianne Pavel",
"url": "https://questionsmedicales.fr/author/Marianne%20Pavel",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine, University Hospital Erlangen, Erlangen, Germany."
}
},
{
"@type": "Person",
"name": "Dermot O'Toole",
"url": "https://questionsmedicales.fr/author/Dermot%20O%27Toole",
"affiliation": {
"@type": "Organization",
"name": "Department of Gastroenterology, St. Vincent's University Hospital and St James's Hospital, And Trinity College Dublin, The University of Dublin, Dublin, Ireland."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Serum prostate specific antigen is a good indicator of prostatic volume in men with benign prostatic hyperplasia.",
"datePublished": "2022-12-15",
"url": "https://questionsmedicales.fr/article/36546488",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.4102/phcfm.v14i1.3736"
}
},
{
"@type": "ScholarlyArticle",
"name": "Granulomatous prostatitis: mimicking locally advanced prostate adenocarcinoma.",
"datePublished": "2023-10-17",
"url": "https://questionsmedicales.fr/article/37850783",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.23750/abm.v94i5.13751"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prostatic Artery Embolization Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: A Cost-Effectiveness Analysis.",
"datePublished": "2022-08-12",
"url": "https://questionsmedicales.fr/article/35964881",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jvir.2022.08.006"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prostate organogenesis.",
"datePublished": "2022-06-21",
"url": "https://questionsmedicales.fr/article/35726824",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1242/dev.200394"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prostatic Urethral Length as a Predictor for Surgery in Benign Prostatic Hyperplasia.",
"datePublished": "2023-03-10",
"url": "https://questionsmedicales.fr/article/36974872",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.33314/jnhrc.v20i3.4613"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Tumeurs",
"item": "https://questionsmedicales.fr/mesh/D009369"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs par siège",
"item": "https://questionsmedicales.fr/mesh/D009371"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs du thorax",
"item": "https://questionsmedicales.fr/mesh/D013899"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Tumeurs du thorax - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Tumeurs du thorax",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Tumeurs du thorax",
"description": "Comment diagnostiquer une tumeur thoracique ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels marqueurs tumoraux sont associés aux tumeurs thoraciques ?\nQuelle est l'importance de l'histologie ?\nLes examens génétiques sont-ils utiles ?",
"url": "https://questionsmedicales.fr/mesh/D013899?mesh_terms=Prostate#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Tumeurs du thorax",
"description": "Quels sont les symptômes courants des tumeurs thoraciques ?\nLa perte de poids est-elle un symptôme ?\nLes tumeurs thoraciques causent-elles des saignements ?\nComment la fatigue se manifeste-t-elle ?\nLes symptômes varient-ils selon le type de tumeur ?",
"url": "https://questionsmedicales.fr/mesh/D013899?mesh_terms=Prostate#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Tumeurs du thorax",
"description": "Comment prévenir les tumeurs thoraciques ?\nLe dépistage est-il utile ?\nL'alimentation joue-t-elle un rôle ?\nL'exercice physique aide-t-il à prévenir ?\nLes vaccinations sont-elles importantes ?",
"url": "https://questionsmedicales.fr/mesh/D013899?mesh_terms=Prostate#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Tumeurs du thorax",
"description": "Quels traitements sont disponibles pour les tumeurs thoraciques ?\nLa chirurgie est-elle toujours nécessaire ?\nQu'est-ce que la chimiothérapie néoadjuvante ?\nLa radiothérapie est-elle efficace ?\nY a-t-il des traitements ciblés disponibles ?",
"url": "https://questionsmedicales.fr/mesh/D013899?mesh_terms=Prostate#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Tumeurs du thorax",
"description": "Quelles complications peuvent survenir ?\nLes tumeurs thoraciques peuvent-elles causer des douleurs ?\nComment les tumeurs affectent-elles la respiration ?\nLes tumeurs peuvent-elles provoquer des caillots sanguins ?\nQuelles sont les complications post-chirurgicales ?",
"url": "https://questionsmedicales.fr/mesh/D013899?mesh_terms=Prostate#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Tumeurs du thorax",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque ?\nLes antécédents médicaux jouent-ils un rôle ?\nL'exposition professionnelle est-elle un facteur ?\nLe mode de vie influence-t-il le risque ?",
"url": "https://questionsmedicales.fr/mesh/D013899?mesh_terms=Prostate#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une tumeur thoracique ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par imagerie (radiographie, scanner) et biopsie."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent la tomodensitométrie, l'IRM et la bronchoscopie."
}
},
{
"@type": "Question",
"name": "Quels marqueurs tumoraux sont associés aux tumeurs thoraciques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les marqueurs comme le CEA et le CA 125 peuvent être utilisés pour le suivi."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de l'histologie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'histologie permet de déterminer le type de tumeur et son agressivité."
}
},
{
"@type": "Question",
"name": "Les examens génétiques sont-ils utiles ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils aident à identifier des mutations spécifiques pour le traitement ciblé."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants des tumeurs thoraciques ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent la toux persistante, la douleur thoracique et l'essoufflement."
}
},
{
"@type": "Question",
"name": "La perte de poids est-elle un symptôme ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la perte de poids inexpliquée peut être un signe de tumeur thoracique."
}
},
{
"@type": "Question",
"name": "Les tumeurs thoraciques causent-elles des saignements ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent provoquer des hémoptysies, c'est-à-dire des saignements dans les voies respiratoires."
}
},
{
"@type": "Question",
"name": "Comment la fatigue se manifeste-t-elle ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "La fatigue peut être persistante et s'aggraver avec l'évolution de la maladie."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de tumeur ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier selon le type et la localisation de la tumeur."
}
},
{
"@type": "Question",
"name": "Comment prévenir les tumeurs thoraciques ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le tabagisme et l'exposition à des agents cancérigènes aide à prévenir."
}
},
{
"@type": "Question",
"name": "Le dépistage est-il utile ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le dépistage précoce peut aider à détecter les tumeurs à un stade précoce."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut réduire le risque de développer des tumeurs."
}
},
{
"@type": "Question",
"name": "L'exercice physique aide-t-il à prévenir ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut contribuer à réduire le risque de cancer."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles importantes ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations, comme contre le HPV, peuvent réduire le risque de cancers associés."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les tumeurs thoraciques ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chirurgie, la chimiothérapie et la radiothérapie."
}
},
{
"@type": "Question",
"name": "La chirurgie est-elle toujours nécessaire ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la chirurgie dépend du stade et de la localisation de la tumeur."
}
},
{
"@type": "Question",
"name": "Qu'est-ce que la chimiothérapie néoadjuvante ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est un traitement administré avant la chirurgie pour réduire la taille de la tumeur."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle efficace ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est souvent utilisée pour traiter les tumeurs non opérables ou en complément."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements ciblés disponibles ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des thérapies ciblées sont disponibles pour certains types de tumeurs spécifiques."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la métastase, l'infection et l'insuffisance respiratoire."
}
},
{
"@type": "Question",
"name": "Les tumeurs thoraciques peuvent-elles causer des douleurs ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent provoquer des douleurs thoraciques dues à la pression sur les nerfs."
}
},
{
"@type": "Question",
"name": "Comment les tumeurs affectent-elles la respiration ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent obstruer les voies respiratoires, entraînant des difficultés respiratoires."
}
},
{
"@type": "Question",
"name": "Les tumeurs peuvent-elles provoquer des caillots sanguins ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent augmenter le risque de thrombose veineuse profonde."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications post-chirurgicales ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent inclure des infections, des saignements et des problèmes respiratoires."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le tabagisme, l'exposition à l'amiante et les antécédents familiaux sont des facteurs clés."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de tumeurs thoraciques augmente avec l'âge."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de cancer augmentent le risque de développer des tumeurs thoraciques."
}
},
{
"@type": "Question",
"name": "L'exposition professionnelle est-elle un facteur ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines professions exposent à des substances cancérigènes, augmentant le risque."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 18/03/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Publications dans "Tumeurs du thorax" :
3 publications dans cette catégorie
Affiliations :
Mayo Clinic, Rochester, MN, USA.
Publications dans "Tumeurs du thorax" :
2 publications dans cette catégorie
Affiliations :
Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, MN.
Publications dans "Tumeurs du thorax" :
2 publications dans cette catégorie
Affiliations :
Department of Medicine, University Hospital Erlangen, Erlangen, Germany.
Publications dans "Tumeurs du thorax" :
2 publications dans cette catégorie
Affiliations :
Department of Gastroenterology, St. Vincent's University Hospital and St James's Hospital, And Trinity College Dublin, The University of Dublin, Dublin, Ireland.
Publications dans "Tumeurs du thorax" :
2 publications dans cette catégorie
Affiliations :
Division of Pancreatic Surgery, Pancreas Translational & Clinical Research Center, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Publications dans "Tumeurs du thorax" :
2 publications dans cette catégorie
Affiliations :
University of Milan, Department of Health Sciences and S.C. Anatomia Patologica, ASST Santi Paolo e Carlo, Milan, Italy.
Publications dans "Tumeurs du thorax" :
2 publications dans cette catégorie
Affiliations :
Institute of Pathology, University of Cologne, Cologne, Germany.
Publications dans "Tumeurs du thorax" :
2 publications dans cette catégorie
Affiliations :
Department of Pathology, Texas Tech University Health Sciences Center, El Paso, TX, USA.
Publications dans "Tumeurs du thorax" :
2 publications dans cette catégorie
Affiliations :
CRIMM-Centro Ricerca e Innovazione delle Malattie Mieloproliferative, Azienda Ospedaliera-Universitaria Careggi, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Publications dans "Tumeurs du thorax" :
2 publications dans cette catégorie
Affiliations :
Mayo Clinic, Rochester, MN, USA.
Publications dans "Tumeurs du thorax" :
2 publications dans cette catégorie
Affiliations :
University Clinic Wuppertal, University of Witten/Herdecke, Wuppertal, Germany. hm.kvasnicka@patho-uwh.de.
Publications dans "Tumeurs du thorax" :
2 publications dans cette catégorie
Affiliations :
Institute of Pathology, University Medical Center Mainz, JGU-Mainz, Mainz 55131, Germany.
Joint Unit Immunopathology, Institute of Pathology, University Medical Center, JGU-Mainz and TRON, Translational Oncology at the University Medical Center, JGU-Mainz, Mainz 55131, Germany.
Institute of Pathology, Heidelberg University Hospital, Heidelberg 69120, Germany.
Publications dans "Tumeurs du thorax" :
2 publications dans cette catégorie
Affiliations :
Department of Haematology, Queen's University, Belfast, United Kingdom.
Publications dans "Tumeurs du thorax" :
2 publications dans cette catégorie
Affiliations :
Department of Pathology, Erzincan Binali Yildirim University, Mengucek Gazi Training and Research Hospital, Erzincan, Turkey.
Publications dans "Tumeurs du thorax" :
2 publications dans cette catégorie
Affiliations :
Department of Pathology, Erzincan Binali Yildirim University, Mengucek Gazi Training and Research Hospital, Erzincan, Turkey.
Publications dans "Tumeurs du thorax" :
2 publications dans cette catégorie
Affiliations :
Department of Pathology, Eskisehir City Hospital, Eskisehir, Turkey.
Publications dans "Tumeurs du thorax" :
2 publications dans cette catégorie
Affiliations :
Department of Pathology, Erzincan Binali Yildirim University, Mengucek Gazi Training and Research Hospital, Erzincan, Turkey.
Publications dans "Tumeurs du thorax" :
2 publications dans cette catégorie
Affiliations :
Department of Pathology, Erzincan Binali Yildirim University, Mengucek Gazi Training and Research Hospital, Erzincan, Turkey.
Publications dans "Tumeurs du thorax" :
2 publications dans cette catégorie
Affiliations :
Department of Pathology, Erzincan Binali Yildirim University, Mengucek Gazi Training and Research Hospital, Erzincan, Turkey.
Publications dans "Tumeurs du thorax" :
Benign prostatic hyperplasia (BPH) is the most common cause of bladder outlet obstruction in men over the age of 50 years. An association between the prostate specific antigen (PSA), International Pro...
To determine the correlation between the PSA, IPSS and PV in men of African descent....
This was a cross sectional analysis involving 92 patients diagnosed as having symptomatic BPH at the Ho Teaching Hospital....
The data were collected using standardised questionnaires. The IPSS determined urinary symptom severity. The PV was determined using a transabdominal ultrasound machine. Serum PSA was retrieved from t...
The mean PV was 61.04 cm3 ± 21.95 cm3, the mean PSA was 4.21 ng/mL ± 3.85 ng/mL, and mean IPSS of 21.59 ± 3.78. The Pearson's correlation between PV and PSA was 0.283 (p = 0.01), between PV and IPSS w...
This study showed that serum PSA has a positive correlation with PV. However, IPSS had no significant association with PSA or PV in patients with BPH.Contribution: This study provides insights into th...
We report the case of a 63-year-old male who came to the urology clinic with an increasing value of the prostate specific antigen and an asymmetrical enlargement at the digital rectal examination. The...
To compare the cost effectiveness of prostatic artery embolization (PAE) with that of transurethral resection of the prostate (TURP) for the treatment of medically refractory benign prostatic hyperpla...
A cost-effectiveness analysis with Markov modeling was performed, comparing the clinical course after PAE with that after TURP for 3 years. Probabilities were obtained from the available literature, a...
Base case calculation showed comparable outcomes (PAE, 2.845 QALY; TURP, 2.854 QALY), with a cost difference of $3,104 (PAE, $2,934; TURP, $6,038). The incremental cost-effectiveness ratio was $360,24...
PAE is a cost-effective strategy to treat medically refractory BPH, resulting in comparable health benefits at a lower cost than that of TURP even when accounting for extreme alterations in adverse ev...
Prostate organogenesis begins during embryonic development and continues through puberty when the prostate becomes an important exocrine gland of the male reproductive system. The specification and gr...
Benign prostatic hyperplasia is associated with structural and morphological changes including elongation of prostatic urethral length. The aim of our study was to assess whether prostatic urethral le...
This prospective observational study was conducted over a 12-months duration. All the patients who presented with lower urinary tract symptoms secondary to benign prostatic hyperplasia were evaluated ...
A total of 153 patients were included in the study. Eighty-three (54.2%) patients underwent surgery during the study period. Prostate volume, intravesical prostatic protrusion, post-void residual volu...
BPH patients with longer PUL may require surgical management. PUL measured by TRUS may be a predicting factor for the need of surgery in BPH Keywords: Benign prostatic hyperplasia; lower urinary tract...
Biomarkers of DNA damage repair deficiency provide opportunities for personalized treatment with immunotherapy. However, there is limited research on the immune microenvironment of adeno-neuroendocrin...
A retrospective medical record review of 66 patients with prostate cancer (PCa) was performed. PCa samples from the 66 patients were analyzed using immunohistochemical staining for the detection of ch...
Twenty patients presented with adeno-NEPC, whereas 46 presented with adeno-PCa. The median age of patients at PCa diagnosis was 67.86 ± 7.05 years (68.65 ± 7.23 years, adeno-NEPC; 67.52 ± 7.02 years, ...
Our study revealed clinicopathological manifestations of adeno-NEPC and some possible predictive factors significantly associated with better outcomes in patients with adeno-NEPC. These findings might...
The purpose of the study was to evaluate the diagnostic significance of two new and a few clinical markers for prostate cancer (PCa) at various prostate volumes (PV)....
The study subjects were divided into two groups. Among them, there were 70 cases in the PV ≤30 ml group (benign prostatic hyperplasia [BPH]: 32 cases, PCa: 38 cases) and 372 cases in the PV > 30 ml gr...
In the PV ≤30 ml group, the diagnostic parameters based on prostate-specific antigen (PSA) had a decreased diagnostic significance for PCa. In the PV > 30 ml group, PSAD (AUC = 0.709), AVR (AVR = Age/...
Choosing appropriate indicators for different PVs could contribute to the early screening and diagnosis of PCa. The difference in the diagnostic value of two new indicators (A-PSAD and AVR), and PSAD ...
Holmium laser enucleation of the prostate (HoLEP) is a size-independent surgical option for treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) with excellent, durable ...
This study aims to compare the ability of the PHI versus tPSA test to predict the presence of PCa in our population....
A prospective observational study was performed. We included patients with tPSA ≥ 2.5 ng/ml, biopsy naïve or previous negative biopsy, undergoing a blood test, which includes tPSA, fPSA, and p2PSA, an...
140 men were included. Fifty-seven (40.7%) had a positive prostate biopsy result (Group A), and 83 (59.3%) had a negative biopsy result (Group B). The mean age was similar in both groups (mean ± stand...
The PHI test improves PCa detection compared to tPSA in our population....
We compare Prostate Health Index, Prostate Health Index density, and PSA density in predicting clinically significant prostate cancer in MRI-guided prostate biopsy....
This is a multicenter evaluation of prospectively maintained prostate biopsy databases at 10 urology centers. Men with Prostate Health Index and MRI-guided targeted and systematic prostate biopsy perf...
A total of 1,215 men were analyzed. Prostate cancer and clinically significant prostate cancer were diagnosed in 51% (617/1,215) and 35% (422/1,215) of men, respectively. Clinically significant prosta...
Prostate Health Index density outperformed Prostate Health Index or PSA density in clinically significant prostate cancer detection in men with multiparametric MRI performed, and further reduced unnec...